RESUMEN
Approximately 20% of head and neck squamous cell carcinomas (HNSCCs) exhibit reduced methylation on lysine 36 of histone H3 (H3K36me) due to mutations in histone methylase NSD1 or a lysine-to-methionine mutation in histone H3 (H3K36M). Whether such alterations of H3K36me can be exploited for therapeutic interventions is still unknown. Here, we show that HNSCC models expressing H3K36M can be divided into two groups: those that display aberrant accumulation of H3K27me3 and those that maintain steady levels of H3K27me3. The former group exhibits reduced proliferation, genome instability, and heightened sensitivity to genotoxic agents like PARP1/2 inhibitors. Conversely, H3K36M HNSCC models with constant H3K27me3 levels lack these characteristics unless H3K27me3 is elevated by DNA hypomethylating agents or inhibiting H3K27me3 demethylases KDM6A/B. Mechanistically, H3K36M reduces H3K36me by directly impeding the activities of the histone methyltransferase NSD3 and the histone demethylase LSD2. Notably, aberrant H3K27me3 levels induced by H3K36M expression are not a bona fide epigenetic mark because they require continuous expression of H3K36M to be inherited. Moreover, increased sensitivity to PARP1/2 inhibitors in H3K36M HNSCC models depends solely on elevated H3K27me3 levels and diminishing BRCA1- and FANCD2-dependent DNA repair. Finally, a PARP1/2 inhibitor alone reduces tumor burden in a H3K36M HNSCC xenograft model with elevated H3K27me3, whereas in a model with consistent H3K27me3, a combination of PARP1/2 inhibitors and agents that up-regulate H3K27me3 proves to be successful. These findings underscore the crucial balance between H3K36 and H3K27 methylation in maintaining genome instability, offering new therapeutic options for patients with H3K36me-deficient tumors.
Asunto(s)
Neoplasias de Cabeza y Cuello , Histonas , Humanos , Histonas/metabolismo , Lisina/metabolismo , Carcinoma de Células Escamosas de Cabeza y Cuello/genética , Metilación , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Neoplasias de Cabeza y Cuello/genética , Inestabilidad Genómica/genéticaRESUMEN
Fatty acid uptake and altered metabolism constitute hallmarks of metastasis1,2, yet evidence of the underlying biology, as well as whether all dietary fatty acids are prometastatic, is lacking. Here we show that dietary palmitic acid (PA), but not oleic acid or linoleic acid, promotes metastasis in oral carcinomas and melanoma in mice. Tumours from mice that were fed a short-term palm-oil-rich diet (PA), or tumour cells that were briefly exposed to PA in vitro, remained highly metastatic even after being serially transplanted (without further exposure to high levels of PA). This PA-induced prometastatic memory requires the fatty acid transporter CD36 and is associated with the stable deposition of histone H3 lysine 4 trimethylation by the methyltransferase Set1A (as part of the COMPASS complex (Set1A/COMPASS)). Bulk, single-cell and positional RNA-sequencing analyses indicate that genes with this prometastatic memory predominantly relate to a neural signature that stimulates intratumoural Schwann cells and innervation, two parameters that are strongly correlated with metastasis but are aetiologically poorly understood3,4. Mechanistically, tumour-associated Schwann cells secrete a specialized proregenerative extracellular matrix, the ablation of which inhibits metastasis initiation. Both the PA-induced memory of this proneural signature and its long-term boost in metastasis require the transcription factor EGR2 and the glial-cell-stimulating peptide galanin. In summary, we provide evidence that a dietary metabolite induces stable transcriptional and chromatin changes that lead to a long-term stimulation of metastasis, and that this is related to a proregenerative state of tumour-activated Schwann cells.
Asunto(s)
Grasas de la Dieta/farmacología , Metástasis de la Neoplasia , Ácido Palmítico/farmacología , Células de Schwann/efectos de los fármacos , Animales , Línea Celular Tumoral , Cromatina/genética , Cromatina/metabolismo , Grasas de la Dieta/administración & dosificación , Proteína 2 de la Respuesta de Crecimiento Precoz/metabolismo , Matriz Extracelular/química , Matriz Extracelular/metabolismo , Femenino , Galanina/metabolismo , Histonas/química , Histonas/metabolismo , Humanos , Masculino , Ratones , Ácido Palmítico/administración & dosificación , Células de Schwann/metabolismoRESUMEN
Failure mechanisms associated with silicon-based anodes are limiting the implementation of high-capacity lithium-ion batteries. Understanding the aging mechanism that deteriorates the anode performance and introducing novel-architectured composites offer new possibilities for improving the functionality of the electrodes. Here, the characterization of nano-architectured composite anode composed of active amorphous silicon domains (a-Si, 20 nm) and crystalline iron disilicide (c-FeSi2 , 5-15 nm) alloyed particles dispersed in a graphite matrix is reported. This unique hierarchical architecture yields long-term mechanical, structural, and cycling stability. Using advanced electron microscopy techniques, the nanoscale morphology and chemical evolution of the active particles upon lithiation/delithiation are investigated. Due to the volumetric variations of Si during lithiation/delithiation, the morphology of the a-Si/c-FeSi2 alloy evolves from a core-shell to a tree-branch type structure, wherein the continuous network of the active a-Si remains intact yielding capacity retention of 70% after 700 cycles. The root cause of electrode polarization, initial capacity fading, and electrode swelling is discussed and has profound implications for the development of stable lithium-ion batteries.
RESUMEN
Approximately 20% of head and neck squamous cell carcinomas (HNSCC) exhibit reduced methylation on lysine 36 of histone H3 (H3K36me) due to mutations in histone methylase NSD1 or a lysine-to-methionine mutation in histone H3 (H3K36M). Whether such alterations of H3K36me can be exploited for therapeutic interventions is still unknown. Here, we show that HNSCC models expressing H3K36M can be divided into two groups: those that display aberrant accumulation of H3K27me3 and those that maintain steady levels of H3K27me3. The first group shows decreased proliferation, genome instability, and increased sensitivity to genotoxic agents, such as PARP1/2 inhibitors. In contrast, the H3K36M HNSCC models with steady H3K27me3 levels do not exhibit these characteristics unless H3K27me3 levels are elevated, either by DNA hypomethylating agents or by inhibiting the H3K27me3 demethylases KDM6A/B. Mechanistically, we found that H3K36M reduces H3K36me by directly impeding the activities of the histone methyltransferase NSD3 and the histone demethylase LSD2. Notably, we found that aberrant H3K27me3 levels induced by H3K36M expression is not a bona fide epigenetic mark in HNSCC since it requires continuous expression of H3K36M to be inherited. Moreover, increased sensitivity of H3K36M HNSCC models to PARP1/2 inhibitors solely depends on the increased H3K27me3 levels. Indeed, aberrantly high H3K27me3 levels decrease BRCA1 and FANCD2-dependent DNA repair, resulting in higher sensitivity to DNA breaks and replication stress. Finally, in support of our in vitro findings, a PARP1/2 inhibitor alone reduce tumor burden in a H3K36M HNSCC xenograft model with elevated H3K27me3, whereas in a H3K36M HNSCC xenograft model with consistent H3K27me3 levels, a combination of PARP1/2 inhibitors and agents that upregulate H3K27me3 proves to be successful. In conclusion, our findings underscore a delicate balance between H3K36 and H3K27 methylation, essential for maintaining genome stability. This equilibrium presents promising therapeutic opportunities for patients with H3K36me-deficient tumors.
RESUMEN
Germanium is a promising active material for high energy density anodes in Li-ion batteries thanks to its good Li-ion conduction and mechanical properties. However, a deep understanding of the (de)lithiation mechanism of Ge requires advanced characterizations to correlate structural and chemical evolution during charge and discharge. Here we report a combined operando X-ray diffraction (XRD) and ex situ 7Li solid-state NMR investigation performed on crystalline germanium nanoparticles (c-Ge Nps) based anodes during partial and complete cycling at C/10 versus Li metal. High-resolution XRD data, acquired along three successive partial cycles, revealed the formation process of crystalline core-amorphous shell particles and their associated strain behavior, demonstrating the reversibility of the c-Ge lattice strain, unlike what is observed in the crystalline silicon nanoparticles. Moreover, the crystalline and amorphous lithiated phases formed during a complete lithiation cycle are identified. Amorphous Li7Ge3 and Li7Ge2 are formed successively, followed by the appearance of crystalline Li15Ge4 (c-Li15Ge4) at the end of lithiation. These results highlight the enhanced mechanical properties of germanium compared to silicon, which can mitigate pulverization and increase structural stability, in the perspective for developing high-performance anodes.
RESUMEN
Species diversity can be affected by the structure of vegetation, which may vary in height, density, and distribution of trees, shrubs, and other plant types, configuring different types of habitats. In this study, we evaluated the diversity of sarcosaprophagous Sarcophagidae communities inhabiting the remnant representative habitats protected in Ciervo de los Pantanos National Park: grasslands, forests, and wetlands. We hypothesized that the abundance and diversity of flesh flies would be higher in the grasslands and wetlands than in the forest patches. Samplings were carried out in each habitat type using baited traps during the four seasons in 2015, 2016, and 2019. We collected 585 sarcophagid flies of 17 species. Fifteen species were recorded in grasslands, twelve in the wetlands, and seven in the forests, Tricharaea (Sarcophagula) occidua (Fabricius) (Diptera: Sarcophagidae) being the most abundant (58.3% of the total sample). As expected, the highest abundance was recorded in grasslands whereas the lowest was found in forests. In addition, flesh fly abundance was affected by season. Sarcophagid assemblages differed between habitats and the overall dissimilarity was mainly explained by nestedness. This study provides important information about sarcosaprophagous sarcophagid flies in a little-studied protected natural area in Argentina, which is fundamental for their conservation and useful in forensic investigations.
Asunto(s)
Dípteros , Sarcofágidos , Animales , Ecosistema , Bosques , Parques RecreativosRESUMEN
BACKGROUND: Within the hematopoietic compartment, fibromodulin (FMOD) is almost exclusively expressed in chronic lymphocytic leukemia (CLL) lymphocytes. We set out to determine whether FMOD could be of help in diagnosing borderline lymphoproliferative disorders (LPD). METHODS: We established 3 flow cytometry-defined groups (CLL [n = 65], borderline LPD [n = 28], broadly defined as those with CLLflow score between 35 and -20 or discordant CD43 and CLLflow, and non-CLL LPD [n = 40]). FMOD expression levels were determined by standard RT-PCR in whole-blood samples. Patients were included regardless of lymphocyte count but with tumor burden ≥40%. RESULTS: FMOD expression levels distinguished between CLL (median 98.5, interquartile range [IQR] 37.8-195.1) and non-CLL LPD (median 0.012, IQR 0.003-0.033) with a sensitivity and specificity of 1. Most borderline LPDs were CD5/CD23/CD200-positive with no loss of B-cell antigens and negative or partial expression of CD43. 16/22 patients with available cytogenetic analysis showed trisomy 12. In 25/28 (89%) of these patients, FMOD expression levels fell between CLL and non-CLL (median 3.58, IQR 1.06-6.21). DISCUSSION: This study could suggest that borderline LPDs may constitute a distinct group laying in the biological spectrum of chronic leukemic LPDs. Future studies will have to confirm these results with other biological data. Quantification of FMOD can potentially be of help in the diagnosis of phenotypically complex LPDs.
Asunto(s)
Fibromodulina/sangre , Citometría de Flujo/métodos , Leucemia Linfocítica Crónica de Células B/sangre , Trastornos Linfoproliferativos/sangre , Anciano , Anciano de 80 o más Años , Citodiagnóstico/métodos , Diagnóstico Diferencial , Femenino , Regulación Neoplásica de la Expresión Génica/genética , Humanos , Leucemia Linfocítica Crónica de Células B/patología , Recuento de Linfocitos , Trastornos Linfoproliferativos/patología , MasculinoRESUMEN
The (de)lithiation process and resulting atomic and nanoscale morphological changes of an a-Si/c-FeSi2/graphite composite negative electrode are investigated within a Li-ion full cell at several current rates (C-rates) and after prolonged cycling by simultaneous operando synchrotron wide-angle and small-angle X-ray scattering (WAXS and SAXS). WAXS allows the probing of the local crystalline structure. In particular, the observation of the graphite (de)lithiation process, revealed by the LixC6 Bragg reflections, enables access to the respective capacities of both graphite and active silicon. Simultaneously and independently, information on the silicon state of (de)lithiation and nanoscale morphology (1 to 60 nm) is obtained through SAXS. During lithiation, the SAXS intensity in the region corresponding to characteristic distances within the a-Si/c-FeSi2 domains increases. The combination of the SAXS/WAXS measurements over the course of several charge/discharge cycles, in pristine and aged electrodes, provides a complete picture of the C-rate-dependent sequential (de)lithiation mechanism of the a-Si/c-FeSi2/graphite anode. Our results indicate that, within the composite electrode, the active silicon volume does not increase linearly with lithium insertion and point toward the important role of the electrode morphology to accommodate the nanoscale silicon expansion, an effect that remains beneficial after cell aging and most probably explains the excellent performance of the composite material.
RESUMEN
Metastasis remains the leading cause of cancer-related deaths worldwide, and our inability to identify the tumour cells that colonize distant sites hampers the development of effective anti-metastatic therapies. However, with recent research advances we are beginning to distinguish metastasis-initiating cells from their non-metastatic counterparts. Importantly, advances in genome sequencing indicate that the acquisition of metastatic competency does not involve the progressive accumulation of driver mutations; moreover, in the early stages of tumorigenesis, cancer cells harbour combinations of driver mutations that endow them with metastatic competency. Novel findings highlight that cells can disseminate to distant sites early during primary tumour growth, remaining dormant and untreatable for long periods before metastasizing. Thus, metastatic cells must require local and systemic influences to generate metastases. This hypothesis suggests that factors derived from our lifestyle, such as our diet, exert a strong influence on tumour progression, and that such factors could be modulated if understood. Here, we summarize the recent findings on how specific metabolic cues modulate the behaviour of metastatic cells and how they influence the genome and epigenome of metastatic cells. We also discuss how crosstalk between metabolism and the epigenome can be harnessed to develop new anti-metastatic therapies.
Asunto(s)
Metástasis de la Neoplasia/patología , Neoplasias/metabolismo , Neoplasias/patología , Animales , Progresión de la Enfermedad , Epigénesis Genética , Humanos , Neoplasias/genética , Células Madre Neoplásicas/metabolismo , Células Madre Neoplásicas/patología , Microambiente TumoralRESUMEN
Alzheimer's disease (AD) is characterized by two neuropathological hallmarks: senile plaques, which are composed of amyloid-ß (Aß) peptides, and neurofibrillary tangles, which are composed of hyperphosphorylated tau protein. Aß peptides are derived from sequential proteolytic cleavage of the amyloid precursor protein (APP). In this study, we identified a so far unknown mode of regulation of APP protein synthesis involving the MID1 protein complex: MID1 binds to and regulates the translation of APP mRNA. The underlying mode of action of MID1 involves the mTOR pathway. Thus, inhibition of the MID1 complex reduces the APP protein level in cultures of primary neurons. Based on this, we used one compound that we discovered previously to interfere with the MID1 complex, metformin, for in vivo experiments. Indeed, long-term treatment with metformin decreased APP protein expression levels and consequently Aß in an AD mouse model. Importantly, we have initiated the metformin treatment late in life, at a time-point where mice were in an already progressed state of the disease, and could observe an improved behavioral phenotype. These findings together with our previous observation, showing that inhibition of the MID1 complex by metformin also decreases tau phosphorylation, make the MID1 complex a particularly interesting drug target for treating AD.
RESUMEN
During a review of material from the project "Assessment of the current status of the faunistic conservation objects from the Gorgona Island: a holistic approach to the ecological evaluation of the Gorgona Natural National Park", conducted 2010â2011, a male specimen of Pazius Navás, 1913 (Mecoptera: Bittacidae) was found. The genus had been previously recorded in Colombia in the Amazonas and Cundinamarca departments. The specimen described here differs from other species of Pazius by the absence of the aedeagus ventral process, the presence of seven short dorsal spines at the epandrium and shape of the ventral process. This finding represents the first record of the order Mecoptera for Gorgona Island, a new species of Pazius, and the expansion of the genus distribution in Colombia. A detailed morphological description of Pazius gorgonensis n. sp. and an identification key for species of the genus are presented.
Asunto(s)
Insectos/clasificación , Distribución Animal , Estructuras Animales/anatomía & histología , Estructuras Animales/crecimiento & desarrollo , Animales , Tamaño Corporal , Ecosistema , Femenino , Insectos/anatomía & histología , Insectos/crecimiento & desarrollo , Islas , Masculino , Tamaño de los Órganos , Parques RecreativosRESUMEN
Lung cancer is the number one cause of cancer-related deaths worldwide. DNA methylation is an epigenetic mechanism that regulates gene expression, and disease-specific methylation changes can be targeted as biomarkers. We have compared the genome-wide methylation pattern in tumor and tumor-adjacent normal lung tissue from four lung adenocarcinoma (LAC) patients using DNA methylation microarrays and identified 74 differentially methylated regions (DMRs). Eighteen DMRs were selected for validation in a cohort comprising primary tumors from 52 LAC patients and tumor-adjacent normal lung tissue from 32 patients by methylation-sensitive high resolution melting (MS-HRM) analysis. Significant increases in methylation were confirmed for 15 DMRs associated with the genes and genomic regions: OSR1, SIM1, GHSR, OTX2, LOC648987, HIST1H3E, HIST1H3G/HIST1H2BI, HIST1H2AJ/HIST1H2BM, HOXD10, HOXD3, HOXB3/HOXB4, HOXA3, HOXA5, Chr1(q21.1).A, and Chr6(p22.1). In particular the OSR1, SIM1 and HOXB3/HOXB4 regions demonstrated high potential as biomarkers in LAC. For OSR1, hypermethylation was detected in 47/48 LAC cases compared to 1/31 tumor-adjacent normal lung samples. Similarly, 45/49 and 36/48 LAC cases compared to 3/31 and 0/31 tumor-adjacent normal lung samples showed hypermethylation of the SIM1 and HOXB3/HOXB4 regions, respectively. In conclusion, this study has identified and validated 15 DMRs that can be targeted as biomarkers in LAC.
Asunto(s)
Adenocarcinoma/diagnóstico , Biomarcadores de Tumor/genética , Neoplasias Pulmonares/diagnóstico , Adenocarcinoma/genética , Adenocarcinoma/metabolismo , Adenocarcinoma del Pulmón , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Biomarcadores de Tumor/metabolismo , ADN/aislamiento & purificación , ADN/metabolismo , Metilación de ADN , Proteínas de Homeodominio/genética , Humanos , Pulmón/metabolismo , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Análisis de Secuencia por Matrices de Oligonucleótidos , Transición de Fase , Proteínas Represoras/genética , Factores de Transcripción/genéticaRESUMEN
INTRODUCCIÓN. Las bacteriemias causadas por Enterobacteriaceae resistentes a carbapenémicos se asocian con altas tasas de mortalidad a diferencia de las bacteriemias causadas por Enterobacteriaceae sensibles a carbapenémicos. Los hallazgos clínicos y de laboratorio son importantes para determinar los esquemas terapéuticos y su pronóstico; su diagnóstico precoz resulta esencial para un manejo adecuado. OBJETIVO. Relacionar valores de marcadores sanguíneos y bioquímicos en bacteriemias causadas por Enterobacteriaceae resistentes a carbapenémicos. MATERIALES Y MÉTODOS. Estudio analítico transversal. Población de 427 y muestra de 224 datos de hemocultivos positivos para Enterobacteriaceae de pacientes atendidos en el Hospital de Especialidades Carlos Andrade Marín en el periodo mayo 2016 a julio 2018. Criterios de inclusión: i) al menos un hemocultivo positivo; ii) recuperación del aislado de CRE o CSE y iii) recolección simultanea de muestras de sangre y pruebas de laboratorio. Criterios de exclusión: i) bacteriemias polimicrobianas; ii) valores fuera de rango y iii) reportes sin valores numéricos. El análisis de datos se realizó mediante el programa estadístico International Business Machines Statistical Package for the Social Sciences versión 24.0. RESULTADOS. Se demostró que el recuento de leucocitos [OR 1,21 (95% IC: 1,03-1,43)], el recuento de plaquetas [OR 1,65 (95% IC: 1,37-1,98)] y el tiempo parcial de tromboplastina [OR 1,29 (95% IC: 1,04-1,60)] fueron buenas variables predictoras independientes, mediante análisis de regresión logística multivariante. CONCLUSIÓN. La trombocitopenia y el tiempo parcial de tromboplastina prolongado se asociaron con bacteremia causada por Enterobacteriaceae resistentes a carbapenémicos.
INTRODUCTION. Bacteremias caused by carbapenem-resistant Enterobacteriaceae are associated with high mortality rates in contrast to bacteremias caused by carbapenem-sensitive Enterobacteriaceae. Clinical and laboratory findings are important in determining therapeutic regimens and prognosis; early diagnosis is essential for appropriate management. OBJECTIVE. To relate blood and biochemical marker values in bacteremia caused by carbapenem-resistant Enterobacteriaceae. MATERIALS AND METHODS. Cross-sectional analytical study. Population of 427 and sample of 224 blood culture data positive for Enterobacteriaceae from patients attended at the Carlos Andrade Marín Specialties Hospital in the period May 2016 to July 2018. Inclusion criteria: i) at least one positive blood culture; ii) recovery of CRE or CSE isolate and iii) simultaneous collection of blood samples and laboratory tests. Exclusion criteria: i) polymicrobial bacteremia; ii) out-of-range values and iii) reports without numerical values. Data analysis was performed using the statistical program International Business Machines Statistical Package for the Social Sciences version 24.0. RESULTS. Leukocyte count [OR 1.21 (95% CI: 1.03-1.43)], platelet count [OR 1.65 (95% CI: 1.37- 1.98)] and partial thromboplastin time [OR 1.29 (95% CI: 1.04-1.60)] were shown to be good independent predictor variables, by multivariate logistic regression analysis. CONCLUSION. Thrombocytopenia and prolonged partial thromboplastin time were associated with bacteremia caused by carbapenem-resistant Enterobacteriaceae.
Asunto(s)
Humanos , Masculino , Femenino , Preescolar , Niño , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Adulto Joven , Bacteriemia/diagnóstico , Bacteriemia/sangre , Infecciones por Enterobacteriaceae/diagnóstico , Infecciones por Enterobacteriaceae/sangre , Enterobacteriaceae Resistentes a los Carbapenémicos , Tiempo de Tromboplastina Parcial , Recuento de Células Sanguíneas , Coagulación Sanguínea , Proteína C-Reactiva/análisis , Biomarcadores/sangre , Pruebas de Sensibilidad Microbiana , Modelos Logísticos , Estudios Transversales , Ácido Láctico/sangre , Creatinina/sangre , Diagnóstico Precoz , Albúminas/análisis , Polipéptido alfa Relacionado con Calcitonina/sangreRESUMEN
We investigated whether peroxisome proliferator-activated receptor gamma (PPARgamma) could be involved in the modulation of the amyloid cascade causing Alzheimer's disease. Inducing expression or activating PPARgamma using synthetic agonists of the thiazolinedione family results in a dramatic decrease in the levels of the amyloid-beta (Abeta) peptide in the conditioned medium of neuronal and non-neuronal cells. PPARgamma does not affect expression or activity of any of the secretases involved in the generation of the Abeta peptide but induces a fast, cell-bound clearing mechanism responsible for the removal of the Abeta peptide from the medium. Although PPARgamma expression is generally low in the CNS, induction of PPARgamma expression during inflammation could be beneficial for inducing Abeta clearance. We confirm that the Abeta clearance mechanism can indeed be induced by PPARgamma activation in primary murine-mixed glia and cortical neuronal cultures. Our results suggest that PPARgamma-controlled mechanisms should be explored further as potential drug targets for Alzheimer's disease treatment.
Asunto(s)
Péptidos beta-Amiloides/metabolismo , Cromanos/farmacología , Neuroglía/efectos de los fármacos , Neuronas/efectos de los fármacos , PPAR gamma/fisiología , Tiazolidinedionas/farmacología , Secretasas de la Proteína Precursora del Amiloide , Anilidas/farmacología , Animales , Ácido Aspártico Endopeptidasas , Línea Celular/efectos de los fármacos , Línea Celular/metabolismo , Línea Celular Tumoral/efectos de los fármacos , Línea Celular Tumoral/metabolismo , Células Cultivadas/efectos de los fármacos , Células Cultivadas/metabolismo , Corteza Cerebral/citología , Medios de Cultivo Condicionados/química , Endopeptidasas/análisis , Endopeptidasas/metabolismo , Humanos , Riñón , Ratones , Neuroblastoma/patología , Neuroglía/metabolismo , Neuronas/metabolismo , PPAR gamma/agonistas , PPAR gamma/antagonistas & inhibidores , PPAR gamma/genética , Fragmentos de Péptidos/metabolismo , Pioglitazona , Procesamiento Proteico-Postraduccional/efectos de los fármacos , Receptor Notch1 , Receptores de Superficie Celular/metabolismo , Proteínas Recombinantes de Fusión/agonistas , Proteínas Recombinantes de Fusión/antagonistas & inhibidores , Proteínas Recombinantes de Fusión/fisiología , Receptores X Retinoide/efectos de los fármacos , Rosiglitazona , Factores de Transcripción/metabolismo , Tretinoina/farmacología , TroglitazonaRESUMEN
The amyloid and tangle cascade hypothesis is the dominant explanation for the pathogenesis of Alzheimer's disease (AD). A complete knowledge of the metabolic pathways leading to beta-amyloid (A beta) production and clearance in vivo and of the pathological events that lead to fibril formation and deposition into plaques is crucial for the development of an 'anti-amyloid' therapeutic strategy. Important advances in this respect have been achieved recently, revealing new candidate drug targets. Among the most promising potential treatments are beta- and gamma-secretase inhibitors, A beta vaccination, Cu-Zn chelators, cholesterol-lowering drugs and non-steroidal anti-inflammatory drugs. Now, the major question is whether these drugs will work in the clinic.
Asunto(s)
Enfermedad de Alzheimer/fisiopatología , Enfermedad de Alzheimer/terapia , Péptidos beta-Amiloides/fisiología , Péptidos beta-Amiloides/antagonistas & inhibidores , Péptidos beta-Amiloides/biosíntesis , Antiinflamatorios no Esteroideos/farmacología , Química Encefálica , Colesterol/metabolismo , Humanos , VacunaciónRESUMEN
Synaptic loss is the major neuropathological correlate of memory decline as a result of Alzheimer's Disease (AD). Synaptic failure appears to depend on the toxic actions of small and soluble amyloid-ß (Aß) oligomers. However, few studies have addressed the mechanism by which aging makes synapses more vulnerable to Aß toxicity. In the present study we analyzed mitochondrial function and morphology and markers of oxidative stress in isolated presynaptic nerve endings from the hippocampus that were exposed to Aß peptide at different ages. We found an age-related decline in mitochondrial activity, reduced antioxidant contents and increased oxidative stress markers in resting and depolarized synaptic terminals. Ultrastructural changes including an increase in mitochondrial size and a significant reduction of synaptic vesicles contents were also observed. In addition, synaptosomes obtained from 24 month old rats were more sensitive to Aß toxicity. These data provide evidence of morphological and biochemical synaptic changes associated with aging that may contribute to exacerbate the damaging effects of Aß.
Asunto(s)
Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/toxicidad , Mitocondrias/ultraestructura , Estrés Oxidativo/fisiología , Sinapsis/patología , Envejecimiento/patología , Enfermedad de Alzheimer/metabolismo , Animales , Hipocampo/metabolismo , Hipocampo/patología , Masculino , Microscopía Electrónica de Transmisión , Mitocondrias/metabolismo , Ratas , Ratas Wistar , Sinapsis/metabolismo , Sinaptosomas/ultraestructuraRESUMEN
Aging is a major risk factor for a large number of disorders and functional impairments. Therapeutic targeting of the aging process may therefore represent an innovative strategy in the quest for novel and broadly effective treatments against age-related diseases. The recent report of lifespan extension in mice treated with the FDA-approved mTOR inhibitor rapamycin represented the first demonstration of pharmacological extension of maximal lifespan in mammals. Longevity effects of rapamycin may, however, be due to rapamycin's effects on specific life-limiting pathologies, such as cancers, and it remains unclear if this compound actually slows the rate of aging in mammals. Here, we present results from a comprehensive, large-scale assessment of a wide range of structural and functional aging phenotypes, which we performed to determine whether rapamycin slows the rate of aging in male C57BL/6J mice. While rapamycin did extend lifespan, it ameliorated few studied aging phenotypes. A subset of aging traits appeared to be rescued by rapamycin. Rapamycin, however, had similar effects on many of these traits in young animals, indicating that these effects were not due to a modulation of aging, but rather related to aging-independent drug effects. Therefore, our data largely dissociate rapamycin's longevity effects from effects on aging itself.
Asunto(s)
Envejecimiento/efectos de los fármacos , Longevidad/efectos de los fármacos , Sirolimus/farmacología , Serina-Treonina Quinasas TOR/antagonistas & inhibidores , Animales , Transformación Celular Neoplásica/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Granuloma/prevención & control , Inmunoglobulinas/sangre , Recuento de Leucocitos , Hígado/efectos de los fármacos , Hígado/patología , Cirrosis Hepática/prevención & control , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Fuerza Muscular/efectos de los fármacos , Consumo de Oxígeno/efectos de los fármacos , Fenotipo , Recuento de Plaquetas , Desempeño Psicomotor/efectos de los fármacos , Análisis de Supervivencia , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/patologíaRESUMEN
Peroxisome proliferator-activated receptor gamma (PPARgamma) activation results in an increased rate of amyloid-beta (Abeta) clearance from the media of diverse cells in culture, including primary neurons and glial cells. Here, we further investigate the mechanism for Abeta clearance and found that PPARgamma activation modulates a cell surface metalloprotease that can be inhibited by metalloprotease inhibitors, like EDTA and phenanthroline, and also by the peptide hormones insulin and glucagon. The metalloprotease profile of the Abeta-degrading mechanism is surprisingly similar to insulin-degrading enzyme (IDE). This mechanism is maintained in hippocampal and glia primary cultures from IDE loss-of-function mice. We conclude that PPARgamma activates an IDE-like Abeta degrading activity. Our work suggests a drugable pathway that can clear Abeta peptide from the brain.
Asunto(s)
Péptidos beta-Amiloides/metabolismo , Insulisina/metabolismo , PPAR gamma/farmacología , Animales , Biotinilación , Caveolinas/farmacología , Células Cultivadas , Clatrina/farmacología , Regulación hacia Abajo/efectos de los fármacos , Electroforesis en Gel de Poliacrilamida , Endocitosis/efectos de los fármacos , Epítopos , Femenino , Glucagón/farmacología , Insulisina/genética , Proteínas de la Membrana/metabolismo , Metaloproteasas/metabolismo , Ratones , Ratones Noqueados , Neprilisina/genética , Neprilisina/metabolismo , Neuroglía/efectos de los fármacos , Neuroglía/metabolismo , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Fenantrolinas/farmacología , Plásmidos/genética , Embarazo , ARN Interferente Pequeño/farmacología , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Comentaremos a continuación un brote de escabiosis sucedido en dos centros de trabajo que pertenecen a una empresa pública y en donde coexisten trabajadores de tres empresas distintas. Pretendemos expresar la importancia de la aplicación de los protocolos existentes y su revisión para aquellas enfermedades poco frecuentes y con posibilidad de convertirse en epidemias, así como la importancia de la coordinación empresarial en aquellos centros de trabajo donde realizan su función dos o más empresas (AU)
We discuss below a scabies outbreak happened in two workplaces belonging to a public company and where coexist workers from three different companies. We intend to express the importance of the implementation of existing protocols and review for those with rare diseases and epidemics become possible, and the importance of business coordination in all cases of prevention and treatment in those workplaces where do function two or more companies (AU)
Asunto(s)
Humanos , Escabiosis/epidemiología , Permetrina/uso terapéutico , Infestaciones por Ácaros/epidemiología , Sarcoptes scabiei/patogenicidad , Brotes de Enfermedades/prevención & controlRESUMEN
Beta-secretase (BACE1) is the rate-limiting protease for the generation of the amyloid beta-peptide (Abeta) in Alzheimer disease. Mice in which the bace1 gene is inactivated are reported to be healthy. However, the presence of a homologous gene encoding BACE2 raises the possibility of compensatory mechanisms. Therefore, we have generated bace1, bace2, and double knockout mice. We report here that BACE1 mice display a complex phenotype. A variable but significant number of BACE1 offspring died in the first weeks after birth. The surviving mice remained smaller than their littermate controls and presented a hyperactive behavior. Electrophysiologically, subtle alterations in the steady-state inactivation of voltage-gated sodium channels in BACE1-deficient neurons were observed. In contrast, bace2 knockout mice displayed an overall healthy phenotype. However, a combined deficiency of BACE2 and BACE1 enhanced the bace1-/- lethality phenotype. At the biochemical level, we have confirmed that BACE1 deficiency results in an almost complete block of Abeta generation in neurons, but not in glia. As glia are 10 times more abundant in brain compared with neurons, our data indicate that BACE2 could indeed contribute to Abeta generation in the brains of Alzheimer disease and, in particular, Down syndrome patients. In conclusion, our data challenge the general idea of BACE1 as a safe drug target and call for some caution when claiming that no major side effects should be expected from blocking BACE1 activity.